My Dumbest Investment In spite of hype I bought early and overpaid
The reader describes buying a niche market leader at a very high price with a P/E near 300, selling at a new high and rebuying cheaper, making 2000 but losing about 15000 overall. The Fool warns against paying any price for top names and hints at the risk of timing and price. The note also includes a trivia answer about Nucor Corp and a merger history.
MENTIONED IN THIS ARTICLE
Alexander Hamilton
Aaron Burr
United States
North Carolina
Oldsmobile
Nuclear Corp. of America
Nucor Corp
Merck Faces 2002 Pressure From Patent Expirations
Merck trading near 52 week lows as 2002 earnings growth stalls due to patent expirations for Prilosec Mevacor and Prinivil. Merck Medco wide profits, overall margins squeeze. If growth returns in 2003 the stock could offer value versus the S&P 500.
MENTIONED IN THIS ARTICLE
Merck
MRE
Merck-Medco
2002 Gadgets Build on Existing Models in Tech Outlook
Portable MP3 players shrink while holding more songs and phones double as handheld computers. Televisions grow larger sharper and cheaper as consumer electronics shift from analog to digital. Wireless Web access expands across PDAs cell phones and laptops with hubs, as makers push affordable converged devices.
MENTIONED IN THIS ARTICLE
San Jose
Calif
Andrew Johnson
Gartner Dataquest
Enderle
Giga Information Group
Casio
Sony
3Com
Audrey
Also Mentioned on This Page
R.X
DoCoMo
Junko Miyazaki
FOMA
Tokyo
Rob
eVilla
Beret
Wall Street
IRS
Giant City
Carbondale
Illinois